Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology
Jan. 21 2022 | Press Release
• miCAR Platform Enables Simultaneous Silencing of
Multiple Gene Targets
• Allogene to Deploy miCAR and other Technologies to Create the Next
Allogeneic Cell Products
SOUTH SAN FRANCISCO, Calif. and GENEVA, Switzerland,
January 11, 2022 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a
clinical-stage biotechnology company pioneering the development of
allogeneic CAR T (AlloCAR T™) products for cancer
and Antion Biosciences, a Swiss cell and gene engineering company, today
announced that they have entered into an
exclusive collaboration and global license agreement for Antion's miRNA
technology (miCAR™) to advance multiplex gene
silencing as an additional tool to develop next generation allogeneic
CAR T products.
Antion is an early-stage research company with foundational miRNA technology. In preclinical studies, Antion has demonstrated proof-of-concept for multiplex gene silencing in an allogeneic CAR T cell model. These studies demonstrated the ability of miCAR™ technology to silence multiple gene targets in a single step and indicate this technology has broad application within cell and gene engineering. Allogene plans to deploy miCAR™ with other technologies to develop next-generation strategies for immune evasion and other advances in allogeneic CAR T therapy.
“We believe that Antion has
one of the few technology options capable of delivering multiplex
gene silencing with a high
degree of specificity and potency”, said Rafael Amado, M.D., Executive Vice
President of Research and Development and
Chief Medical Officer.
“We are excited to be working with Antion to explore how their miCAR technology may advance and accelerate Allogene's research efforts aimed at creating best in class allogeneic cell therapies.”
As part of this agreement, Antion will exclusively collaborate with Allogene on oncology products for a defined period. Allogene will also have exclusive worldwide rights to commercialize products incorporating Antion technology developed during the collaboration. Allogene will provide Antion an upfront cash payment and a preferred equity investment. Allogene will pay Antion developmental and commercial milestones and a single-digit royalty on any product sales. Allogene will also take a seat on Antion's Board of Directors.
represents an exciting validation of the power and flexibility of
our miCAR platform", said Sven Kili,
M.D., Chief Executive Officer.
“We are extremely enthusiastic to be working with Allogene, as the world leader in Allogeneic CAR T therapies to bring next-generation life changing therapies to patients.”
About Antion Biosciences
Antion Biosciences SA is a Swiss cell and gene
engineering company developing highly innovative multiplexed allogeneic
therapies to cure diseases with significant unmet medical needs through
ground-breaking cell engineering. Antion's
proprietary Tunable Expression Modulators (TEM) and miCAR™ technologies
allow efficient, simultaneous multi-gene
silencing and gene addition in a single step, enabling the creation of
multimodal treatments that have the ability to
substantially enhance clinical safety and efficacy. These technologies
are developed using a unique Smart Data approach
to construct design and optimization, ensuring maximum efficiency.
Antion's pipeline is focused on curing challenging
cancer and immunotherapy indications with simple, easy to administer
Learn more about Antion
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San
Francisco, is a clinical-stage biotechnology company pioneering
the development of allogeneic chimeric antigen receptor T cell (AlloCAR
T™) products for cancer. Led by a management
team with significant experience in cell therapy, Allogene is developing
a pipeline of “off-the-shelf” CAR T cell
product candidates with the goal of delivering readily available cell
therapy on-demand, more reliably, and at greater
scale to more patients.
For more information, please visit www.allogene.com, and follow them on Twitter and Linkedin.
Allogene's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability to progress the research
collaboration, Antion's ability to develop a next-generation approach to
immune evasion, the ability to develop and
manufacture new therapies from Antion
technology, and the potential benefits of Antion technology and AlloCAR
T therapy. Various factors may cause differences
between Allogene's expectations and actual results as discussed in
greater detail in Allogene's filings with the SEC,
including without limitation in its Form 10-Q for the quarter ended
September 30, 2021. Any forward- looking statements
that are made in this press release speak only as of the date of this
press release. Allogene assumes no obligation to
update the forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
miCAR™ is a trademark of Antion Biosciences SA.
Antion Biosciences Contact:
Consilium Strategic Communications
Matthew Neal / Chris Gardner / Ashley Tapp
+44 (0)20 3709 5700
Allogene Media/Investor Contact:
Chief Communications Officer